Etiometry, a leader in AI-driven clinical intelligence, today announced the continued expansion of its clinical evidence base in adult critical care, with new data demonstrating the platform’s abili...
Autore: Business Wire
UTSW abstract presented at the 2026 Society of Thoracic Surgeons Annual Meeting builds on strong evidence supporting use of the Etiometry Platform in adult critical care
BOSTON: Etiometry, a leader in AI-driven clinical intelligence, today announced the continued expansion of its clinical evidence base in adult critical care, with new data demonstrating the platform’s ability to identify patient-specific risk and support improved resource utilization. Building on more than a decade of robust pediatric evidence, Etiometry now has multiple adult studies showing how its AI-enabled physiologic indices are intended to bring attention to the patient and support the clinician's review of available physiologic and laboratory data as part of standard evaluation.
Among these is a new study conducted at the University of Texas Southwestern Medical Center (UTSW) in Dallas and presented over the weekend at the 2026 Society of Thoracic Surgeons (STS) Annual Meeting in New Orleans. The study evaluated 71 adult patients undergoing pulmonary thromboendarterectomy (PTE) for chronic thromboembolic pulmonary hypertension (CTEPH). It found that continuous monitoring with the Etiometry Platform identified increases in two of its adjunctive indices in patients who experienced longer ICU and hospital lengths of stay.
CTEPH is a life-threatening, progressive form of pulmonary hypertension caused by unresolved blood clots in the lungs and can lead to severe complications, including right heart failure. In the UTSW study, patients with higher inadequate delivery of oxygen (IDO2) levels within the first 24 hours postoperatively were associated with prolonged length of stay. The IDO2 Index is a proprietary risk index delivered through the Etiometry Platform that leverages continuous physiologic and laboratory data to assess a patient’s risk of inadequate delivery of oxygen, underscoring the potential of Etiometry’s AI-driven indices and suggesting they may help bring attention to changes in patient status that warrant the clinician's review.
“Our rapidly growing adult data demonstrates how Etiometry’s platform consistently delivers value across patient populations and care settings,” said Shane Cooke, president and CEO of Etiometry. “This study is one example of how our physiologic indices can be applied in adult critical care to help teams recognize emerging risk sooner, guide management decisions and optimize care pathways.”
The study highlights the use of AI-enabled clinical intelligence in complex critical care settings. In addition to the UTSW study, other adult evaluations of the Etiometry Platform have demonstrated its utility in areas such as cardiac surgery, circulatory support, and ventilation management - areas where observational studies have evaluated associations between clinical decision support tools and process/utilization measures.
Collectively, these studies highlight the platform’s ability to aggregate and display physiologic and lab data and calculate indices that support clinician review and decision-making as part of standard care. These studies show similar signals to results from published pediatric studies, including:
The IDO2 Index was FDA cleared for adult use in January 2023 (K213423). Since then, multiple studies from leading academic centers have reinforced the value of Etiometry’s predictive analytics in adult environments, extending the company’s evidence base beyond pediatrics and into a broader range of high-acuity care settings.
To read the full UTSW abstract presented at STS, visit https://eppro01.ativ.me/web/planner.php?id=STS26 and type “Etiometry” in the search bar.
For more information about Etiometry, visit Etiometry.com.
Regulatory Use Note: The Etiometry Platform Data Aggregation & Visualization module records and displays near real-time physiologic data from supported bedside devices and is not intended for alarm notification. The Risk Analytics Engine calculates adjunctive indices (e.g., IDO2) that provide partial quantitative information; clinicians should review primary patient data as part of standard evaluations, and clinical decisions should not be based solely on the indices. The findings described here are from a retrospective, observational analysis and do not establish causality; results may vary by site and population.
About Etiometry
Founded in 2010, Etiometry offers FDA-cleared critical care software that records and displays physiologic data from supported devices and calculates adjunctive indices intended to aid clinician review of patient status. By leveraging advanced analytics and AI-powered insights, the company supports care teams in identifying subtle changes in patient condition, enabling timely clinical decision-making and intervention.
Etiometry has received ten FDA clearances and is trusted by leading healthcare institutions worldwide, including top-ranked academic medical centers and pediatric hospitals. The company is committed to advancing patient safety, improving clinical efficiency, and lowering the cost of care through smarter data utilization. To learn more, visit Etiometry.com.
Fonte: Business Wire